Kyndryl reports fiscal Q2 2027 revenue of $3.7B
Kyndryl reported revenues of $3.7 billion and a net income of $59 million for the fiscal second quarter of 2027, while reaffirming its financial outlook.
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Kyndryl reported revenues of $3.7 billion and a net income of $59 million for the fiscal second quarter of 2027, while reaffirming its financial outlook.
Dine Brands Global reported Q3 2026 net income of $4.5 million due to customer demand for Applebee's and IHOP value menus, highlighting successful operational execution.
SelectQuote Inc. reported fiscal 2027 first-quarter revenue of $280.0 million, a decrease from the prior year, alongside improved adjusted EBITDA and operating cash flow. The compa…
Lifecore reported a third-quarter net loss of $40.1 million highlighting growing challenges despite securing new CDMO contracts.
Rapport Therapeutics reported positive Phase 2 trial results for RAP-219 in bipolar mania, and management expects to initiate two Phase 3 trials in 2H 2027.
Geron reported $60.1M net product revenue, up 10% QoQ, and reiterated a high-end revenue guidance of $240M. The company announced a gated commercial launch in European markets to e…
Datadog reported $1.20 billion in Q3 2026 revenue, up 35% year-over-year, despite GAAP operating margin dipping to roughly 6%. The company also launched Scout 1.0 to improve custom…
Viridian reported $24.7M in Lumvoa net product revenue with 100+ patients on therapy in Q3 2026. The company currently holds $955.2M in cash and announced the initiation of a phase…
Shoals Technologies Group reported Q3 2026 revenue of $195.3 million and raised its full-year outlook, driven by strong customer demand and operational improvements. The company re…
uniQure reports 2026 Q3 results; FDA granted Priority Review for AMT-130 with a PDUFA date of May 1, 2027; company expects cash runway into 2030.
Worksport signed a term sheet to acquire a U.S.-manufactured truck bed accessory business to expand its product offerings. This strategic move aims to leverage the company's distri…
MoonLake submitted a BLA for sonelokimab to treat hidradenitis suppurativa, while reporting positive Phase 3 PsA results late in the quarter.
CDW reported strong third quarter financial results with robust growth in net sales and net income per diluted share to $6,754.5 million and $2.46, respectively. The company also a…
Nuvectis reports Q3 2026 financial results and details the in-licensing of two drugs, ciprocopan and NXP200, while awaiting FDA updates before year-end.
RXTHM reported Q3 2026 revenue of $23.9 million and adjusted EBITDA of $5.9 million. The company also amended a license agreement with Green Thumb Industries to raise the Señ…
Criteo reported lower quarterly revenue driven by headwinds but expanded Performance CTV and open AI partnerships. Media spend increased 9% year-over-year.
Seres Therapeutics reported Q3 2026 financial results and announced plans to submit a new study design for SER-155 to the FDA in Q1 2027, which aims to prevent immune checkpoint in…
Wayfair reported Q3 net revenue of $3.4 billion, with U.S. sales growing double digits. The company's adjusted EBITDA increased to $236 million, marking the strongest growth quarte…
SolarEdge Technologies reported Q3 2026 revenue of $326.1 million, missing its previously reduced guidance and down 5.8% from the prior quarter. The company is forecasting weaker f…
Q32 Bio reported solid cash and results for the third quarter, noting that revenue is not material. The company expects to initiate a registration-directed program for bempikibart …